FNDC5 and obesity disorder: Precedent studies on irisin have focused mainly on high intensity intervention applicable to women in obesity (BMI 30.34 ± 1.27) with the average age of 30.15 ± 2.96 or 90% of the target heart rate (THR) [9,52].